Lymphoid-specific tyrosine phosphatase (LYP), which exclusively exists in immune cells and down-regulates T cell receptor signaling (TCR), has becoming a potent target for various autoimmune diseases. Herein, we designed and synthesized imidazolidine-2,4-dione and 2-thioxothiazolidin-4-one derivatives as new LYP inhibitors. Among them, the cinnamic acids-based inhibitors (9p and 9r) displayed good LYP inhibitory activities (IC₅₀ = 2.85–6.95 μM). Especially, the most potent inhibitor 9r was identified as competitive inhibitor (K_i = 1.09 μM) and bind LYP reversibly. Meanwhile, 9r exhibited better selectivity over other phosphatases than known LYP inhibitor A15. Furthermore, compound 9r could regulate TCR associated signaling pathway in Jurkat T cell.

淋巴特异性酪氨酸磷酸酶（LYP）专门存在于免疫细胞中，并下调T细胞受体信号传导（TCR），已成为各种自身免疫疾病的有效靶标。在本文中，我们设计并合成了咪唑烷-2,4-二酮和2-硫代噻唑烷二-4-酮衍生物作为新的LYP抑制剂。其中，基于肉桂酸的抑制剂（9p和9r）表现出良好的LYP抑制活性（IC ₅₀  = 2.85–6.95μM）。特别是，最有效的抑制剂9r被鉴定为竞争性抑制剂（K _i  = 1.09μM），可逆地结合LYP。同时，与已知的LYP抑制剂A15相比，9r对其他磷酸酶的选择性更好。此外，化合物9r可以调节Jurkat T细胞中TCR相关的信号传导途径。